Brooklyn ImmunoTherapeutics Receivables

The latest receivables for BTX is $940K as of December 2025. That compares with $67K in the prior-year period — up 1306.8% year over year. Investors often review this figure alongside Brooklyn ImmunoTherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BTX's receivables moved from $67K to $940K — a 1306.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Brooklyn ImmunoTherapeutics's operating scale or balance-sheet position.

A receivables figure of $940K for BTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BTX's receivables ($940K), review year-over-year change from $67K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Brooklyn ImmunoTherapeutics's receivables against similar Telecommunications names. You can also browse sector and industry screens on Stockcircle for a broader set of Telecommunications companies and their key multiples and fundamentals.